Cardiosense Secures $15.1M in Series A

Cardiosense, a Chicago-based digital health company using artificial intelligence (AI) and multi-sensor devices to enable early heart disease detection, has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners.
 
The company will use the capital to support team expansion, speed product development, and fund an expansive heart failure study.
 
“We’re excited to have our new investors join our mission of combating preventable cardiovascular disease,” Amit Gupta, Cardiosense co-founder and CEO told the press. “Recent data has underscored both the need and potential impact of actionable patient monitoring solutions and this capital allows us to accelerate the clinical development of our platform.”
 
The company’s founding team has been developing the underlying tech for over a decade and Cardiosense will pursue regulatory clearance for its CardioTag clinical-grade, multi-parameter wearable device next year. The company is also building an AI platform to analyze raw physiological signals and develop digital biomarkers to spot at-risk patients and provide guided, personalized therapy.
 
CardioTag’s first application will be to improve congestive heart failure (CHF) management. The company was granted FDA breakthrough status for the early heart failure detection algorithm and plans to begin a nationwide clinical study in 2023 to further refine and validate the algorithm.
 
“Effectively forecasting and preventing the development of acute heart failure remains one of our greatest unmet clinical needs,” said Dr. Liviu Klein, MD, chief of Advanced Heart Failure at UCSF and lead clinical advisor for Cardiosense. “Cardiosense’s technology has the potential to directly address this challenge at a population level by providing an accurate, noninvasive solution for identifying at-risk patients and enabling early, therapeutic interventions.”